Elias Jabbour, MD, and Naval Daver, MD, both of the University of Texas MD Anderson Cancer Center, discuss challenges in TP53-mutated acute myeloid leukemia (AML) in this SOHO Insider podcast episode. Despite advances in other molecular subsets, TP53 AML has seen little meaningful progress in more than two decades. It remains a particularly aggressive form, especially common in older adults and therapy-related cases. Not all TP53 mutations are the same; prognosis worsens with high allelic burden, adverse cytogenetics, or multiple mutations. The episode also looks ahead to emerging strategies that may reshape post-transplant care. Early-phase studies are testing engineered natural killer and CAR T-cell therapies as a new kind of donor lymphocyte infusion. These treatments could be given repeatedly with lower risk of graft-versus-host disease, helping to control minimal residual disease and prevent relapse. Finally, the discussion turns to SOHO’s expanding global mission. With meetings held in Spain, Italy, India and Lebanon, SOHO continues to share education and clinical insight around the world. Listen to more podcast episodes.